Prevalence of Iron Deficiency Anemia in Gynecological Cancer Patients Undergoing Treatment: A Two-Institution Retrospective Study

Anemia in patients with cancer negatively affects their quality of life and cancer outcomes. However, most patients with chemotherapy-induced anemia (CIA) are not appropriately evaluated or treated, and the prevalence of iron deficiency anemia (IDA) in CIA remains unclear. We retrospectively reviewe...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-11, Vol.16 (11), p.e74163
Main Authors: Yagi, Taro, Kinose, Yasuto, Koizumi, Mai, Iwamiya, Tadashi, Ito, Futa, Kubota, Satoshi, Sawada, Kenjiro, Kimura, Tadashi, Takemura, Masahiko, Morishige, Ken-Ichirou
Format: Article
Language:English
Subjects:
Hematology
Obstetrics/Gynecology
Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anemia in patients with cancer negatively affects their quality of life and cancer outcomes. However, most patients with chemotherapy-induced anemia (CIA) are not appropriately evaluated or treated, and the prevalence of iron deficiency anemia (IDA) in CIA remains unclear. We retrospectively reviewed the electronic records of patients with gynecological cancer in two tertiary hospitals, between March 2023 and July 2023, and evaluated their anemia status. We identified 54 patients with CIA, and IDA was found in 74% (40/54) of patients with CIA, including 4% (2/54) with absolute iron deficiency (transferrin saturation (TSAT) < 20% and ferritin < 30 ng/mL), 63% (34/54) with functional iron deficiency (TSAT < 50% and 30 ng/mL < ferritin < 500 ng/mL), and 7% (4/54) with possible functional iron deficiency (TSAT < 50% and 500 ng/mL < ferritin < 800 ng/mL). We found that 74% of patients with CIA under gynecologic cancer treatments were IDA in this study.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.74163